Skip to main content

Table 3 Summary of results per hundred infants from the base case model

From: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom

 

Palivizumab

No prophylaxis

 
 

Costs

QALYs

Costs

QALYs

ICER

CHD infants

£636,108

2,597

£449,120

2,591

£33,216

CLD infants

£569,491

2,613

£440,816

2,606

£19,168

Preterm infants

     

<29 wGA

£367,776

2,622.94

£354,226

2,619.42

£3,845

29-32 wGA

£353,668

2,623.12

£272,481

2,620.43

£30,205

33-35 wGA

£318,079

2,622.90

£73,621

2,620.43

£99,056

  1. Abbreviations: CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, QALY Quality-adjusted life-year, ICER Incremental cost-effectiveness ratio.
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us